Beckley Psytech

News

Psychedelic merger to create AtaiBeckley completes

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

Beckley psychedelic hits the target, unlocking atai merger

The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

Psychedelic merger to create AtaiBeckley completes

Beckley psychedelic hits the target, unlocking atai merger

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

Beckley builds case for its psychedelic depression therapy

atai invests $50m in Beckley Psytech

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Beckley Psytech

Editor's Picks